A Phase I Trial of Farnesyltransferase Inhibitor BMS-214662 (NSC 710086) Escalating to a 24 Hour Continuous Intravenous Infusion in Patients With Solid Tumors
Latest Information Update: 08 Feb 2013
At a glance
- Drugs BMS 214662 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
- 11 Jan 2007 Status changed from suspended to completed
- 27 Sep 2005 New trial record.